安进(AMGN.US)AMG 133启动减重III期临床

智通财经2025-03-07

智通财经APP获悉，3月5日，全球临床试验收录网站clinicaltrials显示，安进(AMGN.US)启动了AMG 133(Maridebart Cafraglutide，MariTide)的两项III期临床试验(MARITIME-1和MARITIME-2)，标志着AMG 133进入III期开发阶段。AMG133是安进自主研发的一款注射频率可达到每4周1次的first-in-class抗体多肽...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2517175213?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-03-07 15:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2517175213","market":"hk","top_or_hot":-1,"title":"安进(AMGN.US)AMG 133启动减重III期临床","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，3月5日，全球临床试验收录网站clinicaltrials显示，安进(AMGN.US)启动了AMG 133(Maridebart Cafraglutide，MariTide)的两项III期临床试验(MARITIME-1和MARITIME-2)，标志着AMG 133进入III期开发阶段。AMG133是安进自主研发的一款注射频率可达到每4周1次的first-in-class抗体多肽...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1258992.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>安进(AMGN.US)AMG 133启动减重III期临床</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n安进(AMGN.US)AMG 133启动减重III期临床\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-07 15:29 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1258992.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，3月5日，全球临床试验收录网站clinicaltrials显示，安进(AMGN.US)启动了AMG 133(Maridebart Cafraglutide，MariTide)的两项III期临床试验(MARITIME-1和MARITIME-2)，标志着AMG 133进入III期开发阶段。AMG133是安进自主研发的一款注射频率可达到每4周1次的first-in-class抗体多肽...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1258992.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1258992.html","article_id":"2517175213","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2517175213","pubTimestamp":1741332593,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，3月5日，全球临床试验收录网站clinicaltrials显示，安进启动了AMG 133的两项III期临床试验，标志着AMG 133进入III期开发阶段。AMG133是安进自主研发的一款注射频率可达到每4周1次的first-in-class抗体多肽偶联药物，由靶向葡萄糖依赖性促胰岛素释放多肽受体的全人源单抗偶联两个GLP-1类似物而成，通过抑制GIPR并激活GLP-1受体来发挥减少食物摄入和调节代谢进而减轻体重和降低血糖的作用。AMG 133的降糖和减重效果已经在II期研究中得到了初步验证。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4566":"资本集团","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4135":"资产管理与托管银行","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4588":"碎股","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4599":"减肥药","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4134":"信息科技咨询与其它服务","III":"信息服务","AMGN":"安进","LU0058720904.USD":"联博国际健康护理基金A","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","BK4581":"高盛持仓","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","AMG":"Affiliated Managers Group Inc","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4534":"瑞士信贷持仓"},"translate_title":"Amgen (AMGN.US) AMG 133 initiates phase III clinical trial for weight loss","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"III":1,"AMGN":1,"AMG":1},"content_text":"智通财经APP获悉，3月5日，全球临床试验收录网站clinicaltrials显示，安进(AMGN.US)启动了AMG 133(Maridebart Cafraglutide，MariTide)的两项III期临床试验(MARITIME-1和MARITIME-2)，标志着AMG 133进入III期开发阶段。AMG133是安进自主研发的一款注射频率可达到每4周1次的first-in-class抗体多肽偶联药物，由靶向葡萄糖依赖性促胰岛素释放多肽受体(GIPR)的全人源单抗偶联两个GLP-1类似物而成，通过抑制GIPR并激活GLP-1受体(GLP-1R)来发挥减少食物摄入和调节代谢进而减轻体重和降低血糖的作用。AMG 133的降糖和减重效果已经在II期研究中得到了初步验证。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2517175213","isCrawlerRequest":true}